Total costs (mean) | 95 % CI | Minimum | 25th percentile | Median | 75th percentile | Maximum | |
---|---|---|---|---|---|---|---|
Overall treatment period (n = 30) | 308,363 | (258,792–357,933) | 152,345 | 208,653 | 270,328 | 340,179 | 637,299 |
First-line treatment (n = 30) | 256,149 | (207,992–304,307) | 149,816 | 186,293 | 208,555 | 261,922 | 637,299 |
Second-line treatment (n = 20) | 518,897 | (431,290–606,504) | 280,977 | 348,454 | 431,758 | 650,541 | 925,339 |
Third-line treatment (n = 8) | 416,251 | (188,316–644,185) | 141,582 | 162,033 | 297,117 | 600,389 | 1,056,666 |
Oxaliplatin-based regimens (n = 13) | 418,463 | (357,413–479,513) | 280,977 | 339,667 | 399,767 | 444,406 | 635,115 |
Irinotecan-based regimens (n = 31) | 215,499 | (188,359–242,639) | 141,867 | 171,990 | 207,516 | 223,415 | 567,549 |
Regimens including molecular targeted agents (n = 11) | 705,460 | (586,733–824,187) | 411,384 | 597,586 | 710,434 | 822,972 | 1,056,666 |